Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

A medspa playbook to turn attention into bookings—clear pages, local SEO, and one-screen scheduling. Start booking more clients today!

The ASH abstract published today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the June 30 th, ...

Data to be featured in two oral presentations on December 8, 2025 –– Broad development program assesses ziftomenib across diverse AML segments ...

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...

Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...

Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study ...

ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company ...

Q3 2025 Earnings Call Transcript October 30, 2025 Capital Clean Energy Carriers Corp. beats earnings expectations. Reported EPS is $0.39, expectations were $0.38. Operator: Thank you for standing by, ...

Hyperke Growth Partners has released detailed case study results demonstrating how direct-to-consumer brands can secure hundreds of retail placement opportunities through systematic outreach to ...

Operator: Good day, and welcome to the Cushman & Wakefield Third Quarter 2025 Earnings Call. [Operator Instructions] please note that this conference is being recorded.

Flushing Financial Corporation (NASDAQ: FFIC) Q3 2025 Earnings Call Transcript October 30, 2025 ...